Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancers
Conditions
Advanced Cancers
Trial Timeline
Feb 1, 2009 → Feb 4, 2018
NCT ID
NCT00836927About Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion
Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion is a phase 2 stage product being developed by Merck for Advanced Cancers. The current trial status is terminated. This product is registered under clinical trial identifier NCT00836927. Target conditions include Advanced Cancers.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancers were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00836927 | Phase 2 | Terminated |
Competing Products
20 competing products in Advanced Cancers